Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis

Future Oncology

Volumn 8, Issue 7, 2012, Pages 859-866

  Schoppmann, Sebastian F ^a   Berghoff, Anna Sophie ^b   Jesch, Bettina ^a   Zacherl, Johannes ^a   Nirtl, Nadine ^c   Jomrich, Gerd ^a   Maroske, Florian ^a   Streubel, Berthold ^a   Mesteri, Ildiko ^a   Birner, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Fachhochschule Campus Wien   (Austria)

Author keywords

D2 40; gastrointestinal stromal tumor; immunohistochemistry; podoplanin; prognostic marker

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PODOPLANIN;

AGED; ANEUPLOIDY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME 1Q; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864480217     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.71     Document Type: Article

References (43)

1. Wrba F. Gastrointestinal stomal tumours, morphology and molecular pathology. Wien. Med. Wochenschr. 159(15-16), 383-388 (2009).
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 438(1), 1-12 (2001).
3. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350), 577-580 (1998).
4. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003).
5. Hou YY, Lu SH, Zhou Y et al. Predictive values of clinical and pathological parameters for malignancy of gastrointestinal stromal tumors. Histol. Histopathol. 24(6), 737-747 (2009).
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70-83 (2006).
7. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw. 5(Suppl. 2), S1-S29; quiz S30 (2007).
8. Martin-Broto J, Gutierrez A, Garcia-Del- Muro X et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study. Ann. Oncol. 21(7), 1552-1557 (2010).
9. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest. 84(7), 874-883 (2004).
10. Maleddu A, Pantaleo MA, Nannini M, Biasco G. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J. Transl Med. 9, 75 (2011).
11. Breiteneder-Geleff S, Soleiman A, Kowalski H et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154(2), 385-394 (1999).
12. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol. Dial. Transplant. 14(Suppl. 1), 9-11 (1999).
13. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res. 21(4A), 2351-2355 (2001).
14. Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D. Podoplanin - A specific marker for lymphatic endothelium expressed in angiosarcoma. Verh. Dtsch. Ges. Pathol. 83, 270-275 (1999).
15. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin. Cancer Res. 7(1), 93-97 (2001).
16. Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol. Rep. 9(3), 455-460 (2002).
17. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 448(4), 493-499 (2006).
18. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol. Int. 55(2), 83-86 (2005).
19. Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE. Impact of podoplanin expression in oral squamous cell carcinoma: Clinical and histopathologic correlations. Virchows Arch. 456(5), 473-482 (2010).
20. Ishizawa K, Komori T, Shimada S, Hirose T. Podoplanin is a potential marker for the diagnosis of ependymoma: A comparative study with epithelial membrane antigen (EMA). Clin. Neuropathol. 28(5), 373-378 (2009).
21. Yuan P, Temam S, El-Naggar A et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107(3), 563-569 (2006).
22. Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: A retrospective study. Dis. Esophagus. 25(1), 72-80 (2012).
23. Hoshino A, Ishii G, Ito T et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res. 71(14), 4769-4779 (2011).
24. Schoppmann SF, Berghoff A, Dinhof C et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat. doi:10.1007/s10549-012-1984-x (2012) (Epub ahead of print).
25. Agaimy A, Carney JA. Lymphatics and D2-40/podoplanin expression in gastrointestinal stromal tumours of the stomach with and without lymph node metastasis: An immunohistochemical study with special reference to the Carney triad. J. Clin. Pathol. 63(3), 229-234 (2010).
26. Kuroda N, Tanida N, Oonishi K et al. Significance of D2-40 expression in the diagnosis of gastrointestinal stromal tumor. Med. Mol. Morphol. 41(2), 109-112 (2008).
27. Sulzbacher I, Birner P, Toma C, Wick N, Mazal PR. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J. Clin. Pathol. 60(7), 804-807 (2007).
28. Sulzbacher I, Dominkus M, Pichlhofer B, Mazal PR. Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone. Pathology 41(7), 630-633 (2009).
29. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: Novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 14(20), 6426-6431 (2008).
30. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int. J. Surg. Pathol. 10(2), 81-89 (2002).
31. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. "Pediatric-type" gastrointestinal stromal tumors in adults: Distinctive histology predicts genotype and clinical behavior. Am. J. Surg. Pathol. 35(4), 495-504 (2011).
32. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 28(5B), 2997-3006 (2008).
33. Huber GF, Fritzsche FR, Zullig L et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int. J. Cancer 129(6), 1404-1409 (2011).
34. Suzuki H, Onimaru M, Yonemitsu Y, Maehara Y, Nakamura S, Sueishi K. Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol. Cancer 9, 287 (2010).
35. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9(4), 261-272 (2006).
36. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br. J. Cancer 96(1), 1-5 (2007).
37. Scholl FG, Gamallo C, Vilaro S, Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J. Cell Sci. 112(Pt 24), 4601-4613 (1999).
38. Peterziel H, Muller J, Danner A et al. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT- AP-1 signaling pathway and promoter methylation. Neuro Oncol. 14(4), 426-439 (2012).
39. Daniels M, Lurkin I, Pauli R et al. Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 312(1), 43-54 (2011).
40. Saigusa S, Mohri Y, Ohi M et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol. Rep. 26(5), 1069-1074 (2011).
41. Kreppel M, Drebber U, Wedemeyer I et al. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol. 47(9), 873-878 (2011).
42. Rahadiani N, Ikeda J, Makino T et al. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann. Surg. Oncol. 17(5), 1311-1323 (2010).
43. Suzuki H, Onimaru M, Koga T et al. High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathol. Res. Pract. 207(2), 111-115 (2011).